close icon

Horizon Pharma Stock Was Cut in Half. Then it Tripled

Horizon Pharma (NASDAQ:HZNP), headquartered in Dublin, Ireland, is a $4.7B biopharmaceutical company operating primarily in the United States. In July 2015, its stock was in the vicinity of $39.50. By May 2017, it was trading under $10 per share.

We first examined Horizon Pharma stock’s prospects in September 2016, when it was searching for direction near the $18 mark. Here is what we found.

Horizon Pharma Elliott Wave analysis

According to our Elliott Wave analysis of HZNP’s weekly logarithmic chart, the rally from under $2 in March 2013 to $39.49 in July 2015 was a textbook five-wave impulse, labeled (1)-(2)-(3)-(4)-(5). This meant the following sharp selloff was probably part of a three-wave (a)-(b)-(c) correction, whose wave (c) down was still remaining.

No matter how good or bad the company’s fundamentals might have been, that wasn’t what we focused on two and a half years ago. The markets are not as rational as some people believe they are. Even the poorest company can go through the roof, and even the strongest can trade in the doldrums sometimes.

Ahead of Horizon Pharma ‘s Elliott Wave Rally

So instead of analyzing the company, we tried to understand the market’s attitude towards it. Back in September 2016, wave (c) was “about to take the stock back to the price area between $9 and $7” and complete the 5-3 wave cycle. The trend was then supposed to resume in the direction of the five-wave impulse. Instead of losing hope, we thought investors should take advantage of this low-risk buying opportunity.

Horizon Pharma climbed to $29.44 last week. The updated chart below visualizes its development since September 2016.

Horizon Pharma Tripled from the Lows in May 2017

Wave (c) dragged the stock down to $9.45. The touted reason for the crash to single digits was the company’s disappointing Q1 2017 report which also included a lowered guidance for the full year. In reality, the stage was set for a plunge in wave (c) long ago.

And just when the outlook was the bleakest, the bulls took the wheel and never looked back. Less than two years later, those who had the courage to buy Horizon Pharma stock below $10 a share multiplied their money by three.

The stock is still below its 2015 high, so we think the bulls’ chances of reaching $40 are quite good. How far can they go past this psychological mark is anyone’s guess at this point.

Did you like this analysis? Our Elliott Wave Video Course can teach you how to uncover the patterns yourself!



Stay informed with our newsletter

Latest Elliott Wave analysis on different topics delivered to you weekly.

Privacy policy
You may also like:

T Rowe Price Vulnerable After Fibonacci Encounter

Founded in 1937 and based in Baltimore, Maryland, T Rowe Price is one of the largest asset management companies in the world. At the end of Q1 2019 its assets under management stood at $1.11T. That is T for trillion. Besides, T Rowe Price is also a public company which is why it is of…

Read More »

Momo Inc. – The Tinder of China Looks Promising

Based in Beijing, China, Momo Inc. operates a mobile-based social and entertainment platform. The company was founded in 2011 and became public in late-2014. The Tinder of China, as Momo is often referred to, first turned a profit in 2015 and has been enjoying strong earnings and revenue growth in the last three years. Momo…

Read More »

TTD Stock: Don’t Let that 8-fold Surge Seduce You

The Trade Desk Inc. provides a self-service omni-channel software platform enabling clients to purchase and manage data-driven digital advertising campaigns. TTD stock is trading on NASDAQ since September 2016. In less than three years, the shares have surged from the IPO price of $28.75 to over $232 earlier this month. Early investors have managed to…

Read More »

Mondi Group: Little Known Firm, Well Known Pattern

Even Mondi Group themselves acknowledge that not too many people have heard their name. “Our name may not be familiar to the public, but our products are” is written on the second page of the company’s 2018 annual report. Mondi, listed on the London Stock Exchange, is a global paper and packaging company, headquartered in…

Read More »

Swedbank to Benefit from a Bullish Elliott Wave Cycle

It took Swedbank, one of Sweden’s biggest financial institutions, ten years to return to its pre-crisis glory. The stock rose from as low as SEK 14.70 in March 2009 to SEK 234 in February 2017 – less than SEK 2 below its February 2007 peak. And just when it looked like a new all-time high…

Read More »

FOSL Stock Ready to Exceed Expectations?

In October 2013, Fossil Group had a market cap of roughly $7.5 billion. The watchmaker was enjoying record sales and profits, which was supposed to propel FOSL stock, then hovering above $130 a share, even higher. Fast-forward six years and the company is currently valued at less than $650 million with the shares barely above…

Read More »

Bristol-Myers: Elliott Wave Setup can Double the Price

Bristol-Myers Squibb is in the process of acquiring Celgene in a $74 billion dollar cash-and-stock deal including debt. The deal faced opposition from hedge funds Wellington Management and Starboard Value, but ultimately gained shareholder approval on April 12th. Arbitrageurs, who aim to profit from the discrepancy between the market price and the deal closing price,…

Read More »

More analyses